Full-Time

Executive Director

PDM Operation and Portfolio Management

Posted on 11/20/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$253k - $305kAnnually

Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor's in science.
  • 18 + years of experience in the pharmaceutical/biotech industry with a sound track record of manufacturing operation, strategic sourcing and supplier management, operational excellence, and organizational leadership, with end-to-end development and manufacturing experience of small molecules.
  • Proven track record of strategic leadership and management with at least 8 years in the leadership role.
  • Demonstrated strong cross-functional team leadership and people management.
  • Good understanding and working experience in drug development and manufacturing with respect to GMP, quality systems, ICH guidelines, FDA, EMA, and associated regulatory requirements.
  • Working experience with management and oversight of the development and manufacturing activities at CDMOs.
  • Strong problem-solving skills with strategic and sound technically driven decision-making ability.
  • Effective written and verbal communication skills and interpersonal skills.
  • Innovative team player with high energy for our dynamic company environment.
Responsibilities
  • Lead global sourcing strategy development and execution to ensure appropriate and robust supply chain to support RVMD pipeline development and commercialization.
  • Lead the efforts to assess/identify potential suppliers with adequate risks and benefits assessment.
  • Provide business operational oversight for the external R&D and manufacturing activities.
  • Lead business review meetings with collective feedback across PDM functions on the overall performance of the CDMOs and CTLs to ensure operational excellence.
  • Establish scalable and robust PDM Portfolio Management systems, structures, and cultures while driving operational advancement and excellence.
  • Collaborate with drug substance (DS), analytical development & QC (ADQC), drug product (DP), supply chain (SC), CMC PM, CMC regulatory and quality (QA) to ensure overall CMC goals are met.
  • Travel to CDMOs for vendor assessment and qualification, as well as supplier oversight as needed.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?